Argenx’s Vyvgart Receives the EC’s Approval for the Treatment of Generalized Myasthenia Gravis
Shots:
- The approval was based on the results from the P-III (ADAPT) trial evaluating the safety & efficacy of Vyvgart (efgartigimod alfa-fcab) vs. PBO in a ratio (1:1) for 26wks. in patients (n=167) with gMG across North America, Europe & Japan
- The results demonstrated the response of anti-AChR Ab positive gMG patients treated with Vyvgart on the MG-ADL scale (68% vs. 30%) & on the QMG scale (63% vs 14%) vs PBO
- Vyvgart is a human IgGI Ab fragment that binds to the neonatal Fc receptor (FcRN) to reduce the circulating IgG autoantibodies. Vyvgart has previously been approved in the US & Japan for the treatment of gMG whereas argenx & Zai Lab have jointly planned to launch Vyvgart in Canada & China
Ref: Globe Newswire | Image: Argenx
Tags
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
